Impact of an Antimicrobial Stewardship Programme on the Prescription of Carbapenems and Quinolones
DOI:
https://doi.org/10.24950/O/244/20/2/2021Keywords:
Antimicrobial Stewardship, Carbapenems, Drug Resistance, Bacterial, QuinolonesAbstract
Introduction: An Antimicrobial Stewardship Programme (AMSP) has been implemented in our hospital in the second semester of 2017. One of the goals was the reduction of the consumption of carbapenems and quinolones. This study aims to evaluate the evolution of the consumption of these drugs during the two years after implementing this programme. Methods: We analyzed the prescriptions of carbapenems and quinolones among inpatients between July 1st 2017 and June 30th 2019. The clinician reviewed each prescription and intervened, when necessary, directly with the prescriber. The consumption was calculated following the Nordic Council definition (2018 update) for the daily defined dose. Results: In the first year we identified 234 (35.0%) non- -conform prescriptions. Recommendations were addressed in 108 cases, of which 83.3% were accepted. The consumption of quinolones and carbapenems was reduced by 18.0% and 8.6%, respectively, relatively to the previous year. In the second year we identified 284 (34.5%) non-conform prescriptions. Recommendations were addressed in 215 cases, of which 94.0% were accepted. The consumption of quinolones and carbapenems was reduced by 55.7% and 10.3%, respectively. Discussion: Throughout this period, we found a reduction in the consumption of quinolones and carbapenems and an increase in compliance with the AMSP recommendations, reflecting a better education for prescription. This favors a more adequate use of antimicrobials, with lesser predisposal to the development of resistance. Conclusion: In our hospital, the AMSP is leading to a reduction in the use of carpabenems and quinolones, with good acceptance of the recommendations by the prescribers.
Downloads
References
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12.
ECDC Joint Technical Report. The bacterial challenge: time to react. Amsterdam: European Centre for Disease Control and Prevention;2009.
Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(Suppl. 2):S82–9.
Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. U.S. Department of Health and Human Services, CDC. Bethesda: CDC; 2019.
Sohn Kim, Covington A, Pamer EG. The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens. Immunol Rev. 2017;279:90–105.
Wright GD. The antibiotic resistome: The nexus of chemical and genetic diversity. Nat Rev Microbiol. 2007;5:175–86.
Barlam TF, Cosgrove SE, Abbo LM, Macdougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62:1197–202.
Fishman N, Patterson J, L S, Srinivasan A, Trivedi KK, Schooneveld T van, et al. Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol. 2012;33:322–7.
Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N. Impact of antimicrobial stewardship in critical care: A systematic review. J Antimicrob Chemother. 2011;66:1223–30.
Plano Nacional para a Segurança dos Doentes (Despacho n.o 1400- A/2015). Diário da República. 2015; 2ª série (N.28):3882(2)-(10).
Direção-Geral da Saúde, Programa de Prevenção e Controlo das Infecções e Resistência aos Antimicrobianos. Plano Nacional de Combate à Resistência aos Antimicrobianos 2019-2023. Direção-Geral da Saúde. 2019.
Berg C, Blix HS, Litleskare I, Rønning M, Strøm H, Granum T. Guidelines for ATC classification and DDD assignment. Oslo: Norwegian Institute of Public Health; Methodology, WHO Collaborating Centre for Drug Statistics; 2017.
Wilcox MH. The tide of antimicrobial resistance and selection. Int J Antimicrob Agents. 2009;34:S6–10.
Fong K, McMullan R. Antimicrobial Therapeutics in Critical Care. Crit Care Horizons. 2015;1:11–21.
Schneider-Lindner V, Delaney JA, Dial S, Dascal A, Suissa S. Antimicrobial drugs and community-acquired methicillin-resistant Staphylococcus aureus, United Kingdom. Emerg Infect Dis. 2007;13:994–1000.
Couderc C, Thiébaut ACM, Lawrence C, Bouchiat C, Herrmann JL, Salomon J, et al. Fluoroquinolone impact on nasal methicillin-resistant and methicillin-sensitive Staphylococcus aureus colonization durations in neurologic long-term-care facilities. Antimicrob Agents Chemother. 2015;59:7621–8.
MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis. 2005;41:435–40.
Lee JA, Kang CI, Joo EJ, Ha YE, Kang SJ, Park SY, et al. Epidemiology and clinical features of community-onset bacteremia caused by extended-
-spectrum β-lactamase-producing Klebsiella pneumoniae. Microb Drug Resist. 2011;17:267–73.
Khawcharoenporn T, Vasoo S, Singh K. Urinary Tract Infections due to Multidrug-Resistant Enterobacteriaceae: Prevalence and Risk Factors in a Chicago Emergency Department. Emerg Med Int. 2013;2013:1–7.
Walker E, Lyman A, Gupta K, Mahoney M V., Snyder GM, Hirsch EB. Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens. Clin Infect Dis. 2016;63:960–5.
Oliphant CM, Green GM. Quinolones: A comprehensive review. Am Fam Physician. 2002;65:455–64.
Berg ML, Crank CW, Philbrick AH, Hayden MK. Efficacy of ertapenem for consolidation therapy of extended-spectrum β-lactamase-producing
gram-negative infections: A case series report. Ann Pharmacother. 2008;42:207–12.
Lartigue MF, Poirel L, Poyart C, Réglier-Poupet H, Nordmann P. Ertapenem resistance of Escherichia coli. Emerg Infect Dis. 2007;13:315–7.
Simões AS, Alves DA, Gregório J, Couto I, Dias S, Póvoa P, Viveiros M, Gonçalves L, Lapão LV. Fighting antibiotic resistance in Portuguese hospitals: Understanding antibiotic prescription behaviours to better design antibiotic stewardship programmes. J Glob Antimicrob Resist. 2018;13:226-30.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
